Dr. Andrea Edginton
Associate Professor, Programmatic Assessment Officer, School of Pharmacy, University of Waterloo, Canada

Background

Dr. Andrea Edginton is an Associate Professor at the School of Pharmacy at the University of Waterloo in Ontario, Canada and co-owner of the PBPK consulting company, Design2Code Inc. Before coming to the University, she helped to develop PK-Sim in the Systems Biology group at Bayer Technology Services in Leverkusen, Germany. Dr. Edginton’s academic research focuses on the development and application of physiologically-based pharmacokinetic (PBPK) models and simulation techniques in both the areas of pharmaceuticals and human health risk assessment. Her research examines how the physiology of sub-populations such as children and patients with disease affect the pharmacokinetics of drugs and how this information can be integrated into PBPK models for the optimization of drug therapy. Dr. Edginton also heads the technical component of the Web-Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo.ca) project that uses population pharmacokinetic model and Bayesian forecasting for tailoring treatment prophylaxis in persons with hemophilia. The service is used by over 120 clinical sites around the globe for over 1700 patients (and counting) and contains the largest PK dataset of factor concentrates.

Key Publications

• Offman E, Edginton AN. 2015. A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide. Journal of Pharmacokinetics and Pharmacodynamics. 42(2):135-50
  
• Maharaj A, Fotaki N, Edginton A. 2015. Parameterization of small intestinal water volume using PBPK modeling. European Journal of Pharmaceutical Science. 67:55-64.
  
• McEneny-King A, Edginton AN, Rao PP. 2015. Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein. Bioorganic & Medicinal Chemistry Letters. 25(2):297-301.
  
• Hu Z, Edginton AN, Laizure SC, Parker RB. 2014. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity - Effects on oseltamivir disposition. Clinical Pharmacokinetics. 53(9): 825-836.
  
• Yun YE, Cotton C, Edginton AN. 2014. Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound. Journal of Pharmacokinetics and Pharmacodynamics. 41(1): 1-14.
  
• Maharaj AR, Edginton AN. 2014. Physiologically based pharmacokinetic modeling and simulation in pediatric drug development. Clinical Pharmacology and Therapeutics: Pharmacometrics Systems Pharmacology. 3:e150.